Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 262-267

  Gertz, Morie A ^a   Lacy, Martha Q ^a   Lust, John A ^a   Greipp, Philip R ^a   Witzig, Thomas E ^a   Kyle, Robert A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMYLOID; AMYLOID P COMPONENT; BETA 2 MICROGLOBULIN; CARMUSTINE; CREATININE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; M PROTEIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOELECTROPHORESIS; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

EID: 0032952933     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.262     Document Type: Article

References (25)

1. Merlini G: Treatment of primary amyloidosis. Semin Hematol 32:60-79, 1995
2. Kyle RA, Greipp PR: Amyloidosis (AL): Clinical and laboratory features in 229 cases. Mayo Clin Proc 58:665-683, 1983
3. Kyle RA, Gertz MA: Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 32:45-59, 1995
4. Kyle RA, Gertz MA, Greipp PR, et al: A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336:1202-1207, 1997
5. Skinner M, Anderson J, Simms R, et al: Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 100:290-298, 1996
6. Reece PA, Kotasek D, Morris RG, et al: The effect of food on oral melphalan absorption. Cancer Chemother Pharmacol 16:194-197, 1986
7. Oken MM, Harrington DP, Abramson N, et al: Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: Results of Eastern Cooperative Oncology Group Study E2479. Cancer 79:1561-1567, 1997
8. Tan SY, Pepys MB, Hawkins PN: Treatment of amyloidosis. Am J Kidney Dis 26:267-285, 1995
9. Gertz MA, Greipp PR, Kyle RA: Classification of amyloidosis by the detection of clonal excess of plasma cells in the bone marrow. J Lab Clin Med 118:33-39, 1991
10. Rocken C, Schweizer EB, Linke RP, et al: The classification of amyloid deposits in clinicopathological practice. Histopathology 29:325-335, 1996
11. Hoshii Y, Takahashi M, Ishihara T, et al: Immunohistochemical classification of 140 autopsy cases with systemic amyloidosis. Pathol Int 44:352-358, 1994
12. Dubrey SW, Cha K, Skinner M, et al: Familial and primary (AL) cardiac amyloidosis: Echocardiographically similar diseases with distinctly different clinical outcomes. Heart 78:74-82, 1997
13. Gertz MA, Kyle RA, Greipp PR, et al: Beta 2-microglobulin predicts survival in primary systemic amyloidosis. Am J Med 89:609-614, 1990
14. Duston MA, Skinner M, Anderson J, et al: Peripheral neuropathy as an early marker of AL amyloidosis. Arch Intern Med 149:358-360, 1989
15. Gertz MA, Kyle RA, Greipp PR: Response rates and survival in primary systemic amyloidosis. Blood 77:257-262, 1991
16. Greipp PR: Prognosis in myeloma. Mayo Clin Proc 69:895-902, 1994
17. Cohen HJ, Lessin LS, Hallal J, et al: Resolution of primary amyloidosis during chemotherapy: Studies in a patient with nephrotic syndrome. Ann Intern Med 82:466-473, 1975
18. Gertz MA, Kyle RA: Amyloidosis: Prognosis and treatment. Semin Arthritis Rheum 24:124-138, 1994
19. Kyle RA, Greipp PR: Primary systemic amyloidosis: Comparison of melphalan and prednisone versus placebo. Blood 52:818-827, 1978
20. Kyle RA, Greipp PR, Garton JP, et al: Primary systemic amyloidosis: Comparison of melphalan/prednisone versus colchicine. Am J Med 79:708-716, 1985
21. Kyle RA, Greipp PR, O'Fallon WM: Primary systemic amyloidosis: Multivariate analysis for prognostic factors in 168 cases. Blood 68:220-224, 1986
22. Dhodapkar MV, Jagannath S, Vesole D, et al: Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma 27:351-356, 1997
23. Gianni L, Bellotti V, Gianni AM, et al: New drug therapy of amyloidoses: Resorption of AL-type deposits with 4′-iodo-4′-deoxydoxorubicin. Blood 86:855-861, 1995
24. Comenzo RL, Vosburgh E, Simms RW, et al: Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients. Blood 88:2801-2806, 1996
25. Comenzo RL, Vosburgh E, Falk RH, et al: Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 91:3662-3670, 1998